"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"

Ocular Redness Clinical Trial

Official title: The Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Preservative-Free Formulation With Lumify® 0.025% in Adult Subjects With Ocular Redness

Status Completed

Clinical Trial Summary

This is a multi-center, double-masked, randomized, active-controlled, parallel-group, efficacy and safety study that will enroll 386 participants at up to six clinical sites. Participants with ocular redness will be randomized to receive either brimonidine tartrate ophthalmic solution 0.025%, preservative-free formulation, or Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will be treated with study drug for approximately 4 weeks.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Erythema
• Ocular Redness

• NCT number: NCT05360784
• Study type: Interventional
• Source: Bausch & Lomb Incorporated
• Status: Completed
• Phase: Phase 3
• Start date: May 13, 2022
• Completion date: November 23, 2022